# Verrica Pharmaceuticals Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Verrica Pharmaceuticals Inc.). ## Overview Verrica Pharmaceuticals Inc. is a U.S.-based dermatology company focused on developing and commercializing prescription therapies for skin diseases. Its commercial product, YCANTH (VP-102), is a physician-administered topical treatment, and the company also has pipeline programs in common warts and basal cell carcinoma. ## Products & services • YCANTH (VP-102) for molluscum contagiosum • YCANTH-Rx pharmacy access service • VP-102 development for common warts • VP-315 program for basal cell carcinoma • U.S. physician sales and market access support - **Commercial dermatology product** (100%) — YCANTH (VP-102) is the company's marketed, physician-administered topical therapy. - **Access and distribution services** (0%) — YCANTH-Rx and pharmacy/wholesaler channels support prescription fulfillment and access. - **Clinical development pipeline** (0%) — Development programs for common warts and basal cell carcinoma extend the product platform. - YCANTH (VP-102) for molluscum contagiosum - YCANTH-Rx pharmacy access service - VP-102 development for common warts - VP-315 program for basal cell carcinoma - U.S. physician sales and market access support ## Customers The company sells primarily to pharmaceutical wholesalers and distributors, which then supply pharmacies, clinics, hospitals, and federal healthcare programs. Its commercial focus is on U.S. physicians who treat pediatric dermatology and dermatology patients, especially those managing molluscum contagiosum. Market access teams also work with commercial, Medicaid, and managed Medicaid payers to support reimbursement and adoption. - **Pharmaceutical wholesalers/distributors** (primary) — Buy YCANTH and distribute it onward to pharmacies, clinics, hospitals, and federal healthcare programs. - **Pediatric dermatologists** (primary) — Prescribe YCANTH for pediatric molluscum contagiosum and are the core clinical audience. - **Dermatologists** (primary) — Use YCANTH in dermatology practices and represent a major physician adoption segment. - **Pediatricians and select primary care HCPs** (secondary) — Help broaden access to treatment beyond specialist dermatology settings. - **Payers and government programs** (primary) — Commercial, Medicaid, and managed Medicaid plans influence coverage and patient access. - Pharmaceutical wholesalers and distributors buy YCANTH for resale - Pediatric dermatologists prescribe for molluscum contagiosum patients - Dermatologists and high-decile dermatology practices are core users - Pediatricians and select primary care HCPs expand treatment reach - Payers and Medicaid programs matter because reimbursement drives access ## Geography Verrica's commercial business is concentrated in the United States, where YCANTH is marketed and shipped. The company also has an out-licensed Japan opportunity through Torii for cantharidin-based products, which extends the platform beyond the U.S. market. Its supply chain includes raw material sourcing from suppliers based in the People's Republic of China, creating upstream geographic exposure. - United States is the core commercial market for YCANTH - U.S. physician sales force targets dermatology and pediatric practices - Japan is covered through Torii's exclusive license for cantharidin products - Raw cantharidin sourcing has exposure to suppliers in China - Commercial access depends on U.S. payer and pharmacy channels ## Strategy Verrica's strategy centers on expanding YCANTH adoption in the U.S. through physician education, consumer awareness, and payer coverage. It is also building a broader cantharidin platform by advancing common-wart and basal-cell-carcinoma programs and by using partnerships to extend reach outside the U.S. - **Grow YCANTH adoption in the U.S.** (short-term) — The commercial product is the main source of revenue and brand recognition. - **Secure and maintain reimbursement access** (short-term) — Coverage determines whether physicians and patients can obtain the product efficiently. - **Advance pipeline indications** (medium-term) — Additional approved uses could diversify revenue beyond molluscum contagiosum. - **Expand geographic reach through partners** (medium-term) — Licensing can extend the platform without building a full international commercial infrastructure. - Expand YCANTH awareness and prescribing among dermatology HCPs - Use consumer education to increase disease awareness and treatment demand - Improve access through payer coverage and pharmacy workflow simplification - Advance common-wart and BCC pipeline programs to broaden the platform - Pursue partnerships for non-U.S. commercialization where appropriate ## Risks The company depends on a single commercial product and on successful reimbursement, physician adoption, and supply continuity. It also faces financing risk, clinical development risk, and competition from established dermatology treatments and future entrants, while raw material sourcing from China adds supply-chain exposure. - **Going-concern and financing risk** [critical] — The company expects to need additional capital to fund commercialization and R&D. - **Single-product concentration** [high] — YCANTH is the only commercial product, so demand changes flow directly into revenue. - **Gross-to-net and returns risk** [high] — Rebates, chargebacks, discounts, and returns can reduce reported net sales. - **Clinical and regulatory risk** [high] — Pipeline programs need successful trials and FDA approvals before they can contribute revenue. - **Supply-chain concentration** [high] — Raw cantharidin is sourced directly or indirectly from suppliers in China. - **Competitive pressure** [medium] — YCANTH competes with OTC products, procedures, off-label therapies, and future entrants. - Single-product dependence makes revenue sensitive to YCANTH adoption - Additional financing may be needed to fund operations and development - Returns, rebates, and chargebacks can materially affect net sales - Clinical trials may fail or delay approvals for pipeline programs - Cantharidin sourcing from China creates supply-chain and geopolitical risk ## Accounting Revenue is recognized under ASC 606 when product is delivered to wholesalers and distributors, but reported net sales are reduced by estimated rebates, chargebacks, discounts, returns, and other gross-to-net items. Because the company has a limited commercial history and a concentrated product base, estimates for returns and other variable consideration can materially change reported revenue and comparability across periods. - **ASC 606 revenue recognition and gross-to-net reserves** — Can materially affect quarterly revenue and margins - **Inventory and cost of product revenue** — Can distort period-to-period gross margin comparability - **Going-concern assessment** — Important for assessing balance-sheet and funding risk - Revenue is recognized at delivery to wholesalers/distributors - Net sales depend on gross-to-net estimates and variable consideration - Returns and rebates can materially change reported product revenue - Inventory and cost of product revenue reflect prior R&D purchases - Going-concern disclosures reflect financing uncertainty --- *Last updated: 2026-04-29T05:07:49.567686+00:00*